ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
Dow Jones
42.732,13
0,80%
Euro vs US Dollar
1,03125
0,44%
Bitcoin
98.099,51
1,24%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Cullinan Therapeutics Inc (CGEM)

  7. Cullinan Therapeutics Inc (CGEM) News

CGEM

Cullinan Therapeutics (CGEM)

Cullinan Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CGEM
DatumZeitQuelleÜberschriftSymbolFirma
20/12/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
20/12/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
20/12/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
16/12/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
14/11/202423h05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
14/11/202416h01GlobeNewswire Inc.Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413h00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
05/11/202413h00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
04/11/202413h00GlobeNewswire Inc.Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
22/10/202421h24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGEMCullinan Therapeutics Inc
16/10/202413h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
16/10/202413h00GlobeNewswire Inc.Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
17/09/202413h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
17/09/202413h00GlobeNewswire Inc.Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
16/09/202413h00GlobeNewswire Inc.Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
14/09/202410h15GlobeNewswire Inc.Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024NASDAQ:CGEMCullinan Therapeutics Inc
09/09/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
05/09/202422h27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
28/08/202414h00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
08/08/202413h00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
05/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGEMCullinan Therapeutics Inc
04/06/202423h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CGEMCullinan Therapeutics Inc
03/06/202414h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
01/06/202413h00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
24/05/202414h00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:CGEMCullinan Therapeutics Inc
23/05/202423h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CGEM

Kürzlich von Ihnen besucht

TG
D7G
Nel ASA
NYSE
NKE
Nike
AMEX
XLF
Financial Select Sector
AMEX
SPY
SPDR S&P 500
COIN
DOGEUSD
Dogecoin
USOTC
BNPQY
BNP Paribas (QX)
TG
NOV
Novo Nordisk
COIN
BTCUSD
Bitcoin
COIN
ETHUSD
Ethereum
DBI
TDXP
Tec DAX
NYSE
DIS
Walt Disney
TG
DBK
Deutsche Bank
USOTC
BASFY
BASF (QX)
CCOM
US500
US 500
COIN
AVAXUSD
Avalanche
DBI
DAX
DAX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten